Kura Oncology (NASDAQ:KURA) Now Covered by Analysts at UBS Group

Investment analysts at UBS Group started coverage on shares of Kura Oncology (NASDAQ:KURA) in a research report issued to clients and investors on Thursday, Briefing.com reports. The brokerage set a “buy” rating and a $27.00 price target on the stock. UBS Group’s price target suggests a potential upside of 58.64% from the company’s previous close.

KURA has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Down 2.0 %

Shares of NASDAQ:KURA opened at $17.02 on Thursday. The firm has a market cap of $1.30 billion, a P/E ratio of -7.84 and a beta of 0.84. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The business has a fifty day simple moving average of $19.41 and a 200 day simple moving average of $20.13. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the prior year, the company earned ($0.53) EPS. Kura Oncology’s revenue for the quarter was up .0% compared to the same quarter last year. Analysts predict that Kura Oncology will post -2.45 earnings per share for the current year.

Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC grew its position in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares during the last quarter. Affinity Asset Advisors LLC increased its position in shares of Kura Oncology by 281.4% during the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock worth $15,581,000 after acquiring an additional 538,957 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.